Literature DB >> 1387684

Evidence for changes in adrenal and testicular steroids during HIV infection.

N Christeff1, S Gharakhanian, N Thobie, W Rozenbaum, E A Nunez.   

Abstract

The serum levels of cortisol, progesterone, 17 alpha-hydroxyprogesterone, dehydroepiandrosterone (DHEA), DHEA sulfate, androstenedione (delta 4), testosterone (T), estrone, and estradiol of HIV+ men and HIV- men were determined by radioimmunoassay. The cortisol, 17 alpha-hydroxyprogesterone, and estrone levels of all HIV+ subjects were 35-55% (p less than 0.01), 25-90% (p less than 0.01), and 30-50% (p less than 0.01) higher, respectively, than those of controls. Androgen levels were very high in Centers for Disease Control (CDC) groups II and III of HIV infection (DHEA, 85%, p less than 0.01; delta 4, 60%, p less than 0.01; T, 30%, p less than 0.05), but much lower in group IVC1 and IVC2. The estradiol levels were significantly elevated only in group IVD (50%, p less than 0.01) and group IVC2 (25%, NS). These results indicate that serum hormone levels are correlated with HIV infection group. The changes in steroid hormone concentrations during the development of HIV infection may have important implications for the immune response of patients. The high cortisol and estrone levels of all groups, the elevated androgen levels in asymptomatic groups, and the low androgens in AIDS patients may form part of the complex network of immunomodulatory factors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387684

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  16 in total

Review 1.  Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals.

Authors:  Vitaly A Kushnir; William Lewis
Journal:  Fertil Steril       Date:  2011-06-30       Impact factor: 7.329

2.  Effect of interferon alpha on high serum androgen concentrations in HIV positive men with Kaposi's sarcoma.

Authors:  N Christeff; S Gharakhanian; N Thobie; E Wirbel; M T Dalle; D Costagliola; E A Nunez; W Rozenbaum
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

Review 3.  Dehydroepiandrosterone and diseases of aging.

Authors:  R R Watson; A Huls; M Araghinikuam; S Chung
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

Review 4.  Management of prostate cancer in HIV-positive patients.

Authors:  Matthew S Wosnitzer; Franklin C Lowe
Journal:  Nat Rev Urol       Date:  2010-04-27       Impact factor: 14.432

5.  Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehydroepiandrosterone sulphate (DHEAS).

Authors:  M Araghi-Niknam; B Liang; Z Zhang; S K Ardestani; R R Watson
Journal:  Immunology       Date:  1997-03       Impact factor: 7.397

6.  Low bone-mineral density in patients with HIV: pathogenesis and clinical significance.

Authors:  Michael T Yin; Elizabeth Shane
Journal:  Curr Opin Endocrinol Diabetes       Date:  2006-12-01

7.  Short circuit: Disaggregation of adrenocorticotropic hormone and cortisol levels in HIV-positive, methamphetamine-using men who have sex with men.

Authors:  Adam W Carrico; Violeta J Rodriguez; Deborah L Jones; Mahendra Kumar
Journal:  Hum Psychopharmacol       Date:  2017-12-21       Impact factor: 1.672

8.  Alterations in the concentrations and binding properties of sex steroid binding protein and corticosteroid-binding globulin in HIV+patients.

Authors:  M E Martin; C Benassayag; C Amiel; P Canton; E A Nunez
Journal:  J Endocrinol Invest       Date:  1992-09       Impact factor: 4.256

9.  Differences in androgens of HIV positive patients with and without Kaposi sarcoma.

Authors:  N Christeff; C Winter; S Gharakhanian; N Thobie; E Wirbel; D Costagliola; E A Nunez; W Rozenbaum
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

Review 10.  HIV infection of the male genital tract--consequences for sexual transmission and reproduction.

Authors:  A Le Tortorec; N Dejucq-Rainsford
Journal:  Int J Androl       Date:  2009-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.